Virtu Financial LLC Takes $605,000 Position in Greenwich LifeSciences, Inc. $GLSI

Virtu Financial LLC purchased a new stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 28,797 shares of the company’s stock, valued at approximately $605,000. Virtu Financial LLC owned 0.21% of Greenwich LifeSciences as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of GLSI. XTX Topco Ltd purchased a new position in Greenwich LifeSciences during the fourth quarter worth $217,000. Man Group plc bought a new stake in shares of Greenwich LifeSciences in the 4th quarter worth about $590,000. Barclays PLC boosted its stake in shares of Greenwich LifeSciences by 11.8% during the 4th quarter. Barclays PLC now owns 9,744 shares of the company’s stock worth $205,000 after purchasing an additional 1,030 shares during the period. State Street Corp boosted its stake in shares of Greenwich LifeSciences by 19.3% during the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after purchasing an additional 15,831 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Greenwich LifeSciences by 109.6% during the 4th quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after purchasing an additional 4,102 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Greenwich LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $47.50.

Greenwich LifeSciences Stock Up 1.6%

GLSI stock opened at $23.75 on Tuesday. Greenwich LifeSciences, Inc. has a twelve month low of $7.78 and a twelve month high of $34.10. The firm has a market cap of $348.65 million, a price-to-earnings ratio of -15.13 and a beta of 1.40. The business’s fifty day simple moving average is $24.88 and its two-hundred day simple moving average is $23.63.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.